Status of vaccine research and development of vaccines for herpes simplex virus (Q40757139)

23 September 2017

Status of vaccine research and development of vaccines for herpes simplex virus (English)

1 reference

23 September 2017

3

Anna Wald

1 reference

23 September 2017

Christine Johnston

1

1 reference

PubMed ID

26973067

23 September 2017

Sami L Gottlieb

series ordinal

2

1 reference

PubMed ID

26973067

23 September 2017

language of work or name

English

0 references

publication date

10 March 2016

1 reference

23 September 2017

5

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

23 September 2017

34

1 reference

23 September 2017

2948-2952

1 reference

23 September 2017

26

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

23 September 2017

1 reference

Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Prevalence and associations of genital ulcer and urethral pathogens in men presenting with genital ulcer syndrome to primary health care clinics in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Incidence of herpes simplex virus type 2 infections in Africa: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Incidence of neonatal herpes simplex virus infections in the United States, 2006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Foreskin inflammation is associated with HIV and herpes simplex virus type-2 infections in Rakai, Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Getting research into policy - Herpes simplex virus type-2 (HSV-2) treatment and HIV infection: international guidelines formulation and the case of Ghana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Once-daily valacyclovir to reduce the risk of transmission of genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

A pooled analysis of the effect of condoms in preventing HSV-2 acquisition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Efficacy results of a trial of a herpes simplex vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Correlate of immune protection against HSV-1 genital disease in vaccinated women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Epidemiology and control of bovine herpesvirus 1 infection in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Genomic, phylogenetic, and recombinational characterization of herpes simplex virus 2 strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Evolution and diversity in human herpes simplex virus genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Genital Herpes in Guinea Pigs: Pathogenesis of the Primary Infection and Description of Recurrent Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Clinician and patient recognition of anogenital herpes disease in HIV positive men who have sex with men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Nomenclature for immune correlates of protection after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Herpes simplex virus type 2 vaccines: new ground for optimism?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

A vaccine strategy that protects against genital herpes by establishing local memory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Identification of novel virus-specific antigens by CD4⁺ and CD8⁺ T cells from asymptomatic HSV-2 seropositive and seronegative donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Immunization with a highly attenuated replication-competent herpes simplex virus type 1 mutant, HF10, protects mice from genital disease caused by herpes simplex virus type 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

A herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.12.076

10.1016/J.VACCINE.2015.12.076

7 January 2021

Identifiers

DOI

1 reference

23 September 2017

1 reference

PubMed ID

26973067